Study of ITI-333 for the treatment of opioid and other substance use disorders, pain, and mood disorders.
Phase of Trial: Phase I
Latest Information Update: 10 May 2018
At a glance
- Drugs ITI-333 (Primary)
- Indications Mood disorders; Pain
- Focus Adverse reactions
- 10 May 2018 According to an Intra-Cellular Therapies media release, the company expected to initiate the clinical studies in 2019.
- 10 May 2018 New trial record